BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

694 related articles for article (PubMed ID: 12192550)

  • 1. Radioiodine therapy and thyrostatic drugs and iodine.
    Moka D; Dietlein M; Schicha H
    Eur J Nucl Med Mol Imaging; 2002 Aug; 29 Suppl 2():S486-91. PubMed ID: 12192550
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Radioiodine therapy of Graves' disease--a dosimetric comparison of various therapy regimens of antithyroid agents].
    Urbannek V; Voth E; Moka D; Schicha H
    Nuklearmedizin; 2001 Aug; 40(4):111-5. PubMed ID: 11556200
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcome of pediatric Graves' disease after treatment with antithyroid medication and radioiodine.
    Ward L; Huot C; Lambert R; Deal C; Collu R; Van Vliet G
    Clin Invest Med; 1999 Aug; 22(4):132-9. PubMed ID: 10497711
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Graves' disease and radioiodine therapy. Is success of ablation dependent on the choice of thyreostatic medication?
    Kobe C; Weber I; Eschner W; Sudbrock F; Schmidt M; Dietlein M; Schicha H
    Nuklearmedizin; 2008; 47(4):153-6. PubMed ID: 18690374
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of carbimazole following radioiodine therapy on radiation dose to the thyroid.
    Gimlette TM; Kocak R; Herbert RG; Squire CR
    Nuklearmedizin; 1981 Apr; 20(2):72-5. PubMed ID: 6165965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pharmacology and dosage of thyrostatic drugs].
    Passath A; Leb G; Warnkross H
    Acta Med Austriaca; 1987; 14(3-4):72-4. PubMed ID: 2447738
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Characterization of therapy failures in radioiodine therapy of Graves' disease without simultaneous antithyroid agents].
    Sabri O; Zimny M; Schreckenberger M; Reinartz P; Nowak B; Ostwald E; Schäfer W; Block S; Setani K; Büll U
    Nuklearmedizin; 2001 Feb; 40(1):1-6. PubMed ID: 11373933
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effect of iodine application during radioiodine therapy in patients with impending therapy failure].
    Urbannek V; Schmidt M; Moka D; Hillger HW; Voth E; Wellner U; Schicha H
    Nuklearmedizin; 2000; 39(4):108-12. PubMed ID: 10919161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effect of antithyroid medication on the effective half-life and uptake of 131-iodine following radioiodine therapy].
    Moka D; Voth E; Schicha H
    Nuklearmedizin; 1997 Apr; 36(3):87-92. PubMed ID: 9162907
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Determination of factors affecting the therapeutic outcome of radioiodine therapy in patients with Graves' disease].
    Sabri O; Schulz G; Zimny M; Schreckenberger M; Zimny D; Wagenknecht G; Kaiser HJ; Dohmen BM; Bares R; Büll U
    Nuklearmedizin; 1998 May; 37(3):83-9. PubMed ID: 9604227
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Stunning in radioiodine therapy of benign thyroid disease. Quantification and therapeutic relevance].
    Krohn T; Meyer PT; Ocklenburg C; Knollmann D; Nowak B; Schaefer WM
    Nuklearmedizin; 2008; 47(6):248-54. PubMed ID: 19057798
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Success rate of radioiodine therapy in Graves' disease: the influence of thyrostatic medication.
    Sabri O; Zimny M; Schulz G; Schreckenberger M; Reinartz P; Willmes K; Buell U
    J Clin Endocrinol Metab; 1999 Apr; 84(4):1229-33. PubMed ID: 10199759
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dosimetry of radioiodine therapy in patients with nodular goiter after pretreatment with a single, low dose of recombinant human thyroid-stimulating hormone.
    Nieuwlaat WA; Hermus AR; Ross HA; Buijs WC; Edelbroek MA; Bus JW; Corstens FH; Huysmans DA
    J Nucl Med; 2004 Apr; 45(4):626-33. PubMed ID: 15073259
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Administration of additional inactive iodide during radioiodine therapy for Graves' disease: who might benefit?
    Dietlein M; Moka D; Reinholz U; Schmidt M; Schomäcker K; Schicha H; Wellner U
    Nuklearmedizin; 2007; 46(3):77-84. PubMed ID: 17549318
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interference of iohexol with radioiodine thyroid uptake in the hyperthyroid cat.
    Peremans K; Vandermeulen E; van Hoek I; Daminet S; Vermeire S; Bacher K
    J Feline Med Surg; 2008 Oct; 10(5):460-5. PubMed ID: 18511320
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of methimazole pretreatment on the efficacy of radioactive iodine therapy in Graves' hyperthyroidism: one-year follow-up of a prospective, randomized study.
    Andrade VA; Gross JL; Maia AL
    J Clin Endocrinol Metab; 2001 Aug; 86(8):3488-93. PubMed ID: 11502768
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term carbimazole intake does not affect success rate of radioactive 131Iodine in treatment of Graves' hyperthyroidism.
    El Refaei SM; Shawkat W
    Nucl Med Commun; 2008 Jul; 29(7):642-8. PubMed ID: 18528187
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radioiodine therapy of benign thyroid disorders: what are the effective thyroidal half-life and uptake of 131I?
    Kobe C; Eschner W; Wild M; Rahlff I; Sudbrock F; Schmidt M; Dietlein M; Schicha H
    Nucl Med Commun; 2010 Mar; 31(3):201-5. PubMed ID: 19907353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of propylthiouracil on subsequent radioactive iodine therapy in Graves' disease.
    Hancock LD; Tuttle RM; LeMar H; Bauman J; Patience T
    Clin Endocrinol (Oxf); 1997 Oct; 47(4):425-30. PubMed ID: 9404440
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Experience with ambulatory radioiodine therapy of hyperthyroidism].
    Róka R; Séra T; Valkusz Z; Julesz J; Csernay L; Pávics L
    Orv Hetil; 1999 Jun; 140(23):1291-5. PubMed ID: 10412264
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.